Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Catalyst Biosciences Inc. (NASDAQ: CBIO).

Full DD Report for CBIO

You must become a subscriber to view this report.


Recent News from (NASDAQ: CBIO)

Catalyst Biosciences to Host a Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it will host a Research and Development Day focu...
Source: GlobeNewswire
Date: December, 10 2018 08:00
Catalyst Biosciences Announces Updated Positive Interim Data from Its Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors
Results demonstrate efficacy of subcutaneous prophylaxis with MarzAA, Catalyst’s high potency engineered FVIIa Data presented at 60 th American Society of Hematology Annual Meeting & Exposition SOUTH SAN FRANCISCO, Calif., Dec. 01, 2018 (GLOBE NEWSWIRE) -- Catalyst Bios...
Source: GlobeNewswire
Date: December, 01 2018 12:00
Catalyst Biosciences Announces Presentation at the 60th American Society of Hematology Annual Meeting & Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Dr. Howard Levy, chief medical officer...
Source: GlobeNewswire
Date: November, 02 2018 08:00
Catalyst Biosciences misses by $0.06
Catalyst Biosciences (NASDAQ: CBIO ): Q3 GAAP EPS of -$0.64 misses by $0.06. More news on: Catalyst Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 01 2018 08:07
Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update
Presented Updated Positive Interim Data from the Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) at Two Scientific Meetings Published Data from Phase 1 Study of Marzeptacog Alfa (Activated) in the Journal of Thrombosis & Haemostasis Ended Q3 with a cash balance of ~$12...
Source: GlobeNewswire
Date: November, 01 2018 08:00
Factors of Influence in 2018, Key Indicators and Opportunity within StoneMor Partners, Catalyst Biosciences, Kennametal, Emergent Biosolutions, Kimball International, and Tailored Brands - New Research Emphasizes Economic Growth
NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of StoneMor Partners L.P. (NYSE:STON), Catalyst Biosciences, Inc. (NASDAQ:CB...
Source: GlobeNewswire
Date: October, 25 2018 07:30
Catalyst Biosciences: Highly Attractive Hemophilia Pipeline With Upcoming Catalysts, Yet Still Trading At Cash Value
Catalyst Biosciences (NASDAQ: CBIO ) is a clinical-stage biotech company focused on the treatment of hemophilia. Over the last year, its stock fluctuated widely, rallying from around USD 3 in August 2017 to above USD 30 in February 2017 before then dropping back to around USD 10 in June 2018 a...
Source: SeekingAlpha
Date: September, 07 2018 05:58
Market Trends Toward New Normal in Shutterstock, CrossAmerica Partners LP, Allegiance Bancshares, Portola Pharmaceuticals, StoneMor Partners, and Catalyst Biosciences - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Shutterstock, Inc. (NYSE:SSTK), CrossAmerica Partners LP (NYSE:CAPL), Al...
Source: GlobeNewswire
Date: September, 05 2018 08:30
Catalyst Biosciences Announces Publication of Marzeptacog Alfa (Activated) Phase 1 Data in The Journal of Thrombosis and Haemostasis
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the peer-reviewed publication of previously reported ...
Source: GlobeNewswire
Date: September, 04 2018 08:00
Catalyst Biosciences to Present at H.C. Wainwright & Co. 20th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., president and chief executiv...
Source: GlobeNewswire
Date: August, 30 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-149.779.539.899.1359,845
2018-12-1310.089.9110.319.8159,516
2018-12-1210.2710.11510.4010.0346,564
2018-12-1110.4010.15510.4010.0536,871
2018-12-1010.2210.2810.359.9563,636

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-145,22524,36021.4491Cover
2018-12-131,87118,47310.1283Cover
2018-12-121,60111,01514.5347Cover
2018-12-111226,2581.9495Cover
2018-12-103,98414,15928.1376Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CBIO.


About Catalyst Biosciences Inc. (NASDAQ: CBIO)

Logo for Catalyst Biosciences Inc. (NASDAQ: CBIO)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $317,356,144 - 05/14/2018
  • Issue and Outstanding: 11,935,169 - 04/30/2018

 


Recent Filings from (NASDAQ: CBIO)

Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 21 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 26 2018

 

 


Daily Technical Chart for (NASDAQ: CBIO)

Daily Technical Chart for (NASDAQ: CBIO)


Stay tuned for daily updates and more on (NASDAQ: CBIO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CBIO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CBIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CBIO and does not buy, sell, or trade any shares of CBIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/